FDA advises restriction in prescription of systemic fluoroquinolones for the treatment of uncomplicated URIs and UTIs

The FDA announced that it requires changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections.

For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options

Following table suggests the alternatives to Fluoroquinolones which should be used as first line antibiotics:

Reference:

https://jamanetwork.com/journals/jama/article-abstract/2565286

Other Related Articles:

CEFTRIAXONE - RINGER LACTATE'S DEADLY INTERACTION
http://www.worldsurgeryforum.net/2017/09/ceftriaxone-ringer-lactates-deadly.html